Phase I dose escalation study of the anti-CD2 monoclonal antibody, siplizumab, with DA-EPOCH-R in aggressive peripheral T-cell lymphomas

Mature T- and natural killer (NK)-cell neoplasms are a heterogeneous group of diseases, accounting for roughly 10% of non-Hodgkin lymphomas in the United States management. Compared to mature, aggr...